(1 - 11 von 13
)
#ATS Galapagos' GLPG1690 Prevented IPF Lung Function Decline
pulmonaryfibrosisnews.com
Read about the results of Galapagos' Phase 2a trial showing that GLPG1690 prevents lung function decline in IPF patients.
GLPG1690 results in IPF published in The Lancet Respiratory
www.globenewswire.com
Dr. Toby Maher et al. describes the FLORA trial results and was ... Dr. Toby Maher, British Lung Foundation Chair in Respiratory Research and ...
Living with Idiopathic Pulmonary Fibrosis (IPF)
www.news-medical.net
By Dr Toby Maher. By Keynote ContributorDr. Toby MaherNational Institute for Health Research Clinician Scientist and. Consultant Physician at ...
NICE says no to expanding scope of Roche’s IPF drug - PharmaTimes
www.pharmatimes.com
Patients in England and Wales with the lung scarring disease idiopathic pulmonary fibrosis will have to wait until their disease has worsened before getting...
sortiert nach Relevanz / Datum